David Tang is a director with the Business Department. His practice emphasizes securities regulation, private investment fund formation, mergers and acquisitions and public and private debt and equity offerings. In his practice, he has worked with companies and investors in a broad range of industries, including the finance, technology and life sciences sectors.

Prior to joining Howard Rice, Mr. Tang practiced general corporate securities law at Cooley Godward LLP.

Representative Matters

• Representation of startup investment manager assembling academic and business professionals to manage new “quantitative” funds.
• Formation of “hybrid” funds to combine project-based energy investing with securities investment.
• Representation of lead underwriter Thomas Weisel Partners in a follow-on public offering by Pharmacyclics, Inc., a developer of novel small-molecule drugs for brain metastases, lung cancer and other oncology indications.
• Representation of lead underwriter Pacific Growth Equities in a follow-on public offering by Dynavax Technologies, a biopharmaceutical company developing therapies bases on immunostimulatory DNA sequences.
• Representation of National Display Systems, Inc., a high performance flat panel display engineering firm, in its leveraged recapitalization by a private equity firm.
• Representation of Urchin Software Corporation, a private web analytics software company, in its sale to Google Inc.
• Representation of U.S. Trust Corporation, a subsidiary of The Charles Schwab Corporation, in its sale of stock to Bank of America Corporation.
  

Education

• J.D., Stanford Law School, 2000
• M.S., Cornell University (National Science Foundation Graduate Student Research Fellow, Mathematics), 1997
• B.S., Massachusetts Institute of Technology (Mathematics, Physics, Sigma Pi Sigma), 1994

Admitted

• California

Memberships

• State Bar of California
• CzechTech, non-profit organization serving Czechs, Czech-Americans and Americans involved in high-tech industries

Awards & Honors